• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • Samples
    • MRI Images
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

EPAD gets a royal welcome at its 3rd General Assembly

2017-05-15News

On 15-17 May, the EPAD project General Assembly took place in Stockholm, under the banner “From Delivery to Data”. It was hosted by the Karolinska Institutet and jointly sponsored by Boehringer Ingelheim and Lundbeck. The meeting provided a chance to gather everyone who work on the EPAD study to discuss its progress and future plans.

The first day began with project leaders Craig Ritchie, Serge van der Geyten and Miia Kivipelto welcoming more than 150 delegates to the meeting. They gave a general overview of the project and introduced the agenda for the coming days. Each WP then had the opportunity to present its remit and progress so far. You can read more about each of the WPs here: http://ep-ad.org/project-structure/.

On 16 May, the General Assembly gathered for its official inauguration by HRH Queen Silvia of Sweden (pictured), who welcomed delegates to Stockholm and the first session of the day on “the future of AD research”. The programme for this second day focussed on the status of the EPAD Longitudinal Cohort Study (LCS) creating an environment for sustained success; the “EPAD enhancement programme”; and the “EPAD Academy”. In addition, Dr Gill Farrar from GE Healthcare was invited to do a presentation on EPAD’s collaboration with its sister project AMYPAD (AMYloid imaging to Prevent Alzheimer’s Disease). There, she gave also an overview of the AMYPAD partners and objectives. For more information on the AMYPAD initiative, follow @IMI_AMYPAD on Twitter and visit its website recently launched, http://amypad.eu/.
Over the lunch break, WP8 Ethical, Legal and Social Implications held a Satellite Symposium on “Conceptualising Alzheimer’s Disease, hosted by Krista Tromp from VUmc Amsterdam. Dr Luc Truyen of Janssen delivered the research perspective, Dr Dianne Gove presented Alzheimer Europe’s position, and finally Dr Edo Richard of Radboud UMC spoke from the physician’s perspective. There was a lively discussion about emerging ethical issues within EPAD during this session, which continued into the WP8 breakout session at the end of the day. There were also dedicated breakout sessions for WP2, 3 and 4 at this time.

The first and final day focused on the Proof of Concept (PoC) Study Platform – progress so far and looking to the future. Presentations were done on PoC master protocol, statistics and CSF cut-off values. In addition, next steps were discussed including governance and operational aspects. Finally, the meeting closed with all delegates invited to the next General Assembly, which will take place in Amsterdam in May 2018.

The highlight was undoubtedly the presence of an Edinburgh-based research participant Eileen Penman, a member of the EPAD Research Participant Panel, who is the first member of this Panel to attend an EPAD consortium meeting. You can read Eileen’s view and thanks to the whole EPAD team as well as impressions from some EPAD researchers in an article reported by the Centre for Dementia Prevention – an EPAD partner- here: http://centrefordementiaprevention.com/2017/05/27/stockholms-warm-welcome-epad-study/

If you want to keep up to date with our progress, you can also follow us on Facebook (https://fr-fr.facebook.com/IMIEPAD/) and Twitter (@IMI_EPAD).

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
The final EPAD dataset is now available to the entire research community
2020-11-30
ALZFORUM
Alzforum conference blog mentions EPAD
2020-11-30
EPAD v1500 dataset
New webpage dedicated to EPAD data and samples on the EPAD website
2020-11-18
ADDI launches new Workbench to foster greater global research innovation and accelerate breakthroughs in Alzheimer’s disease and related dementias
2020-11-17
New paper investigating the prediction of Alzheimer’s disease biomarker status
2020-11-12
The Alzheimer’s Disease Data Initiative supports EPAD
2020-11-06
Latest News
  • The final EPAD dataset is now available to the entire research community
    2020-11-30
  • ALZFORUM
    Alzforum conference blog mentions EPAD
    2020-11-30
  • EPAD v1500 dataset
    New webpage dedicated to EPAD data and samples on the EPAD website
    2020-11-18
  • ADDI launches new Workbench to foster greater global research innovation and accelerate breakthroughs in Alzheimer’s disease and related dementias
    2020-11-17
  • New paper investigating the prediction of Alzheimer’s disease biomarker status
    2020-11-12
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

We would like to thank all our followers! A massive thanks also goes to our research participants & members for all their support! Looking back on the years of the @IMI_EPAD project, here's key pictures took at major events. Have a safe & Happy New Year! youtu.be/FeYsOBOhCeo

reply retweet favorite
8:55 am · 2021-01-18
Twitter
EPAD
EPAD
@IMI_EPAD

The videos from #30AEC are online! Check out the @IMI_EPAD presentations on #data sharing by @rodrigobarnes (@aridhia) & Colin Veal (@uniofleicester). Thanks @IMI2_NEURONET and @AlzheimerEurope for giving us the opportunity to present our work. imi-neuronet.org/2020-virtual… twitter.com/IMI2_NEURONET/…

reply retweet favorite
8:43 am · 2021-01-15
Twitter
EPAD
EPAD
@IMI_EPAD

Authors investigated #data from nine studies, including @IMI_EPAD, comprising a total of 60,004 assessed participants. If you want to explore the #Alzheimer's disease data landscape, visit adata.scai.fraunhofer.de @BirkenbihlC @ApitiusHofmann @ddomingof @Simon_Lovestone @TVB_cloud

reply retweet favorite
7:56 am · 2021-01-11
Twitter
EPAD
EPAD
@IMI_EPAD

Numerous studies have collected #Alzheimer's disease cohort #data sets. @BirkenbihlC and colleagues have evaluated the Alzheimer's disease data landscape from a patient‐level data‐centric perspective. @IMI_EPAD @IMI_EMIF @NACCALZ alz-journals.onlinelibrary.wi…

reply retweet favorite
7:48 am · 2021-01-11
Twitter
EPAD
EPAD
@IMI_EPAD

The final @IMI_EPAD dataset is now available to the entire research community | News | @CORDIS_EU | European Commission europa.eu/!dj89jY

reply retweet favorite
12:55 pm · 2021-01-08
Copyright © 2015-19 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.